The proliferative and metastatic potential of ER-positive breast cancer cells are often governed by the estrogen signalling pathway; hence, estrogen-blocking strategies for hormone-sensitive tumors have been effective in reducing tumor growth. Here, ESR1 is linked to neoplasm.